• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

JVI: A Novel HA-F Protein Subunit Vaccine against Influenza and Respiratory Syncytial Virus

tetano

Editor, Senior Moderator
Published ahead of print 31 July 2013, doi: 10.1128/JVI.01724-13 JVI.01724-13




A Novel HA-F Protein Subunit Vaccine against Influenza and Respiratory Syncytial Virus

Tiffany M. Turner*,
Les P. Jones*,
S. Mark Tompkins* and
Ralph A. Tripp*#

+ Author Affiliations

* Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, Georgia 30602

ABSTRACT

Influenza A virus and respiratory syncytial virus (RSV) cause substantial morbidity and mortality afflicting the ends of the age spectrum during the autumn through winter months in the United States. The benefit of vaccination against RSV and influenza using a subunit vaccine to enhance immunity and neutralizing antibody was investigated. Influenza hemagglutinin (HA) and RSV fusion (F) protein were tested as vaccine components alone and in combination to explore the adjuvant properties of RSV F protein on HA immunity. Mice vaccinated with HA and F exhibited robust immunity that when challenged had reduced viral burden for both influenza and RSV. These studies show an enhancing and cross-protective benefit of F protein for anti-HA immunity.


http://jvi.asm.org/content/early/2013/07/24/JVI.01724-13.abstract
 
Back
Top Bottom